[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

BR112018014643A2 - forma cristalina de [(2r,5r)-5-{[(2s)-2-[(metil{[2-(propan-2-il)-1,3-tiazol-4-il)metil}carbamoil)amino]-4-(morfolin-4-il)butanoil 9amino}-1,6-difenil-hexan-2il]carbamato de 1,3-tiazol-5-ilmetila ou cobicistat - Google Patents

forma cristalina de [(2r,5r)-5-{[(2s)-2-[(metil{[2-(propan-2-il)-1,3-tiazol-4-il)metil}carbamoil)amino]-4-(morfolin-4-il)butanoil 9amino}-1,6-difenil-hexan-2il]carbamato de 1,3-tiazol-5-ilmetila ou cobicistat

Info

Publication number
BR112018014643A2
BR112018014643A2 BR112018014643A BR112018014643A BR112018014643A2 BR 112018014643 A2 BR112018014643 A2 BR 112018014643A2 BR 112018014643 A BR112018014643 A BR 112018014643A BR 112018014643 A BR112018014643 A BR 112018014643A BR 112018014643 A2 BR112018014643 A2 BR 112018014643A2
Authority
BR
Brazil
Prior art keywords
thiazol
methyl
crystalline form
9amino
diphenylhexan
Prior art date
Application number
BR112018014643A
Other languages
English (en)
Inventor
Lai Chiajen
Novoas De Armas Hector
Him Lawrence YU Lok
Hung Chiu Yu Richard
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of BR112018014643A2 publication Critical patent/BR112018014643A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/28—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

a presente invenção refere-se a uma forma cristalina do composto de fórmula (ia), métodos para preparar a forma cristalina do composto de fórmula (ia) e métodos terapêuticos para o uso da forma cristalina do composto de fórmula (ia).
BR112018014643A 2016-01-28 2017-01-24 forma cristalina de [(2r,5r)-5-{[(2s)-2-[(metil{[2-(propan-2-il)-1,3-tiazol-4-il)metil}carbamoil)amino]-4-(morfolin-4-il)butanoil 9amino}-1,6-difenil-hexan-2il]carbamato de 1,3-tiazol-5-ilmetila ou cobicistat BR112018014643A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662288029P 2016-01-28 2016-01-28
PCT/US2017/014761 WO2017132158A1 (en) 2016-01-28 2017-01-24 Crystalline form of 1,3-thiazol-5-ylmethyl [(2r,5r)-5-{[(2s)-2-[(methyl{[2-(propan-2-yl)-1,3-thiazol-4-yl]methyl}carbamoyl)amino]-4-(morpholin-4-yl)butanoyl 9amino}-1,6-diphenylhexan-2-yl]carbamate or cobicistat

Publications (1)

Publication Number Publication Date
BR112018014643A2 true BR112018014643A2 (pt) 2018-12-11

Family

ID=57966186

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018014643A BR112018014643A2 (pt) 2016-01-28 2017-01-24 forma cristalina de [(2r,5r)-5-{[(2s)-2-[(metil{[2-(propan-2-il)-1,3-tiazol-4-il)metil}carbamoil)amino]-4-(morfolin-4-il)butanoil 9amino}-1,6-difenil-hexan-2il]carbamato de 1,3-tiazol-5-ilmetila ou cobicistat

Country Status (15)

Country Link
US (1) US20170217952A1 (pt)
EP (1) EP3408261A1 (pt)
JP (1) JP2019508393A (pt)
KR (1) KR20180101589A (pt)
CN (1) CN108834413A (pt)
AR (1) AR107441A1 (pt)
AU (2) AU2017211118B2 (pt)
BR (1) BR112018014643A2 (pt)
CA (1) CA3011930A1 (pt)
EA (1) EA201891447A1 (pt)
MA (1) MA46513A (pt)
MX (1) MX2018009056A (pt)
SG (1) SG11201806109RA (pt)
TW (1) TW201728582A (pt)
WO (1) WO2017132158A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE026380T2 (en) 2008-05-02 2016-06-28 Gilead Sciences Inc Use of solid carrier particle
CN109384739B (zh) * 2017-08-14 2023-06-02 上海奥博生物医药股份有限公司 一种可比司他新晶型及其制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ME02258B (me) 2006-07-07 2015-12-31 Gilead Sciences Inc Modulatori farmakokinetičkih svojstava terapeutika
HUE026380T2 (en) * 2008-05-02 2016-06-28 Gilead Sciences Inc Use of solid carrier particle
WO2012151165A1 (en) * 2011-05-02 2012-11-08 Gilead Sciences, Inc. Amorphous solid salts

Also Published As

Publication number Publication date
AU2017211118B2 (en) 2020-01-16
MA46513A (fr) 2019-08-21
US20170217952A1 (en) 2017-08-03
JP2019508393A (ja) 2019-03-28
SG11201806109RA (en) 2018-08-30
MX2018009056A (es) 2018-11-19
EA201891447A1 (ru) 2019-03-29
CA3011930A1 (en) 2017-08-03
TW201728582A (zh) 2017-08-16
WO2017132158A1 (en) 2017-08-03
CN108834413A (zh) 2018-11-16
AR107441A1 (es) 2018-05-02
EP3408261A1 (en) 2018-12-05
AU2019283825A1 (en) 2020-01-16
AU2017211118A1 (en) 2018-08-09
KR20180101589A (ko) 2018-09-12

Similar Documents

Publication Publication Date Title
CO2019007711A2 (es) N-[4-fluoro-5-[[(2s,4s)-2-metil-4-[(5-metil-1,2,4-oxadiazol-3-il)metoxi]-1-piperidil]metil]tiazol-2-il]acetamida como inhibidor de oga
CY1122883T1 (el) Ν-((4,6-διμεθυλ-2-οξο-l,2-διυδροπυριδιν-3-υλ)μεθυλ)-5-(αιθυλ (τετραϋδρο-2η-πυραν-4-υλ)αμινο)-4-μεθυλ-4'-(μορφολινομεθυλ)-[l,1'-διφαινυλ]-3-καρβοξαμιδιο υδροβρωμικο για χρηση στη θεραπεια μιας κυτταροπολλαπλασιαστικης διαταραχης του αιματολογικου συστηματος
CY1121433T1 (el) Παραγωγα δικυκλικων ετεροκυκλυλιων ως αναστολεις irak4
IL244787B (en) Polymorph c of n-((4,6-dimethyl-2 oxo-1,2-dihydropyridine-3-yl)methyl)-5-(ethyl(tetrahydro-2h-pyran-4-yl)amino)-4-methyl -4'-(morpholinomethyl)-[1,1'-biphenyl]-3-carboxamide monohydrochloride, methods for its preparation, medical preparations containing it and its use
EA201890731A1 (ru) Модуляторы корового белка гепатита b
BR112017004673A2 (pt) formas cristalinas de 2-(4-(4-etoxi-6-oxo-1,6-diidropiridin-3-ila)-2-fluorofenil)-n-(5-(1,1,1-trifluoro-2-metilpropan-2-il)isoxazol-3-il) acetamida
BR112015009850A2 (pt) compostos de piridila substituídos por heteroarila úteis como moduladores de quinase
PE20170705A1 (es) Nuevos compuestos como inhibidores de ret (reorganizado durante la transfeccion)
DK3220916T3 (da) Fremgangsmåde til behandling af cancer med n-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl(tetrahydro-2h-pyran-4-yl)amino)-4-methyl-4'-(morpholinomethyl)-[1,1'-biphenyl]-3-carboxamid
AR103680A1 (es) Inhibidores selectivos de bace1
EA201491007A1 (ru) Лекарственные составы
CL2018003431A1 (es) Tratamiento de la enfermedad de parkinson.
EP4217352A4 (en) SUBSTITUTED N-(2-(2,6-DIOXOPIPERIDIN-3-YL)-1,3-DIOXOISOINDOLIN-5-YL)ARYLSULFONAMIDE ANALOGUES AS MODULATORS OF THE CEREBLON PROTEIN
BR112016028843A2 (pt) formas sólidas de um composto antiviral
CL2021001629A1 (es) Compuestos de halo-alilamina y uso de los mismos
HUE062353T2 (hu) Eljárás terc-butil-(N-((1R,2S,5S)-2-((2-((5-klórpiridin-2-il)amino)-2-oxoacetil)amino)-5 -(dimetilkarbamoil)ciklohexil)karbamát) elõállítására
BR112018014643A2 (pt) forma cristalina de [(2r,5r)-5-{[(2s)-2-[(metil{[2-(propan-2-il)-1,3-tiazol-4-il)metil}carbamoil)amino]-4-(morfolin-4-il)butanoil 9amino}-1,6-difenil-hexan-2il]carbamato de 1,3-tiazol-5-ilmetila ou cobicistat
BR112013031121A2 (pt) composto de acordo com a fórmula i a v, ou um sal farmaceuticamente aceitável, solvato, polimorfo, ou pró-droga do mesmo; composto; polimorfo de sal cloridrato de 2-morfolino-n-(3-(4-(5-(pirrolidina-1-carbonil)-1h-pirrol-3-il)tiazol-2-il)acetamida (fórmula i); ingrediente ativo constituído do mesmo; composição farmacêutica; polimorfo de 2-morfolino-n-(3-(4-(5-(pirrolidina-1-carbonil)1h-pirrol-3-il)tiazol-2-il)fenil)acetamida (fórmula i); ingrediente ativo constituído do mesmo; uso de um composto ou sal farmaceuticamente aceitável, solvato, polimorfo ou pró-droga do mesmo e uso de um polimorfo ou ingrediente ativo de sal cloridrato de 2-morfolino-n-(3-(4-(5-(pirrolidina-1-carbonil)-1h-pirrol-3-il)tiazol-2il)tiazol-2-il)fenil)acetamida (fórmula i) e uso de um polimorfo ou ingrediente ativo de 2-morfolino-n-(3-(4-(5-(pirrolidina-1-carbonil)-1h1pirrol-3-il)tiazol-2-il)fenil)acetamida(fórmula i) na fabricação de um medicamento
BR112017012646A2 (pt) Formas sólidas compreendendo (1e, 4e)-2-amino- n,n-dipropil-8-(4-(pirrolidina-1-carbonil) fenil)-3h- benzo[b]azepina-4-carboxamida, composições das mesmas, e uso das mesmas
SV2011004017A (es) Tratamiento del cancer de pancreas
MY198008A (en) Crystal of benzofuran derivative free base and preparation method
BR112018074162A2 (pt) composições farmacêuticas adequadas para administração oral e administração parenteral, métodos para prevenir ou tratar infecção fúngica em um indivíduo humano ou animal e para produzir uma composição farmacêutica, e, uso de uma composição farmacêutica.
EP3259267A4 (en) A NOVEL PROCESS FOR THE PREPARATION OF 1,3-THIAZOL-5-YLMETHYL [(2R, 5R) -5 - {[(2S) -2 - [(METHYL {[2- (PROPAN-2-YL) -1) CARBAMATE 3-thiazol-4-yl] methyl} carbamoyl) amino] -4- (morpholin-4-yl) butanoyl] amino} -1,6-DIPHÉNYLHEXAN-2-YL]
ZA201600006B (en) Polymorphic forms of methyl((1s)-1-(((2s)-2-(5-(4'-(2-((2s)-1-((2s)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)-2-pyrrolidinyl)-1h-imidazol-5-yl)-4-biphenylyl)-1h-imidazol-2-yl)-1-pyrrolidinyl) carbonyl)-2-methylpropyl)carbamate and salts thereof
BR112017012965A2 (pt) derivados de fumagilol

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]